---
title: "納斯達克生物科技指數收漲超 2%"
description: "納斯達克生物科技指數上漲超過 2%。Oric Pharma 上漲 33.50%，Erasca 上漲 32.73%，Tango Therapeutics 上漲 20.10%。萊斯康製藥（LXRX）下跌 5.66%，Rapport Therapeutics 下跌 10.46%，Intellia Therapeutics 下跌 22.88%。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/242464376.md"
published_at: "2025-05-29T20:44:12.000Z"
---

# 納斯達克生物科技指數收漲超 2%

> 納斯達克生物科技指數上漲超過 2%。Oric Pharma 上漲 33.50%，Erasca 上漲 32.73%，Tango Therapeutics 上漲 20.10%。萊斯康製藥（LXRX）下跌 5.66%，Rapport Therapeutics 下跌 10.46%，Intellia Therapeutics 下跌 22.88%。

成分股 Oric Pharma 收漲 33.50%，Erasca 漲 32.73%，Tango Therapeutics 漲 20.10% 表現第三。 萊斯康製藥（LXRX）則收跌 5.66% 跌幅第三大，Rapport Therapeutics 跌 10.46%，Intellia Therapeutics 也跌 22.88%。

### Related Stocks

- [ERAS.US - Erasca](https://longbridge.com/zh-HK/quote/ERAS.US.md)
- [TNGX.US - Tango Therapeutics](https://longbridge.com/zh-HK/quote/TNGX.US.md)
- [LXRX.US - 萊斯康制藥](https://longbridge.com/zh-HK/quote/LXRX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Pivotal Vopimetostat Pancreatic Cancer Trial Plan Might Change The Case For Investing In Tango Therapeutics (TNGX) | Tango Therapeutics, Inc. is advancing vopimetostat into a pivotal 300-patient trial for second-line pancreatic cancer, f | [Link](https://longbridge.com/zh-HK/news/276141096.md) |
| Tango Therapeutics CEO Teases Pivotal Vopimetostat Trial, RAS Combo Data at Guggenheim Chat | Tango Therapeutics (NASDAQ:TNGX) is advancing its PRMT5 inhibitor vopimetostat into late-stage development, as announced | [Link](https://longbridge.com/zh-HK/news/276011306.md) |
| Erasca Touts Early ERAS-0015 Responses, Potency Edge in Guggenheim Fireside Chat | Erasca (NASDAQ:ERAS) executives discussed early clinical signals and their RAS-focused pipeline during a Guggenheim fire | [Link](https://longbridge.com/zh-HK/news/275937678.md) |
| Tango Therapeutics CFO Daniella Beckman Reports Disposal of Common Shares | Daniella Beckman, CFO of Tango Therapeutics Inc., reported the disposal of common shares of the company. The full filing | [Link](https://longbridge.com/zh-HK/news/274893551.md) |
| Erasca Inc. General Counsel Ebun Garner Reports Disposal of Common Shares | Ebun Garner, General Counsel & Corporate Secretary of Erasca Inc., reported the disposal of common shares of the company | [Link](https://longbridge.com/zh-HK/news/272012485.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。